



35th EAsDEC Annual Meeting, 5th – 7th June 2025, Liverpool, UK

Concert Room, St George's Hall, Liverpool, L1 1JJ

<https://www.easdec.org/pages/default.asp?id=2>

PROGRAMME

THURSDAY, 5th June 2025

10:30 Diabetic Retinopathy Screening in Europe – Building on 20 years of Progress

Allied event – by invitation – open to EAsDEC delegates

Registration opens at 10:00

This meeting will review progress and lessons learnt in diabetic retinopathy screening across Europe over the last 20 years and develop practical steps to address key current challenges.

Delegates are invited representatives of national professional organisations of diabetes and endocrinology, ophthalmology, and public health, and policy makers and commissioners. A limited number of delegates registered for EAsDEC are welcome to attend. Further details at

www.drscreening2005.org.uk. Registration (no cost) at

<https://www.eventbrite.co.uk/e/diabetic-retinopathy-screening-in-europe-meeting-tickets-1302917083069>.

17:00 Registration for EAsDEC opens

17:30 Roche Sponsored Symposium: Advancing DMO Management with Faricimab

Chair: Prof Ian Pearce

17:30-17:33 Welcome and Introductions. Prof Ian Pearce

17:33-17:43 DMO in Focus: Emerging Evidence in Biomarkers. Prof Stela Vujosevic

17:43-17:53 From Clinical Trials to Real-World: UK FARWIDE Study. Prof Tunde Peto

17:53-18:03 Translating Theory into Practice: Two Case Studies. Prof Ian Pearce

18:03-18:13 Q&A with panel

18:13-18:15 Close. Prof Ian Pearce

18:15 Official opening of EAsDEC

President of EAsDEC, Professor Reinier Schlingemann, Amsterdam, The Netherlands

Chair of Organising Committee, Professor Simon Harding, Liverpool, United Kingdom

18:30 Annual Meeting Welcome Reception

St. George's Hall

Drinks and canapes

20:00 End of day

08:00 Registration

09:00 Introduction and welcome

President of EAsDEC, Professor Reinier Schlingemann, The Netherlands

09:15 Session 1: Clinical research

Chairs: Stela Vujosevic; Ian Pearce

Oral presentations; 6 mins + 3 minutes questions:

09:15 Moderator's introduction to session

09:20 Tunde Peto (UK)

Gold standard versus. ultrawide field imaging for diabetic retinopathy severity: Results from YOSEMITE/RHINE Phase 3 studies

09:29 Edoardo Balduzzi (Italy)

Latent phenotypic Diabetic Macula Oedema clustering and differential treatment responses to intravitreal therapies

09:38 Ian Pearce (UK)

Real-World outcomes of Faricimab among Diabetic Macular Oedema eyes in the UK: 1-Year results from the FARWIDE-DMO Study

09:47 Corinne Fulcher (UK)

Diabetic retinopathy severity after anti-VEGF treatment for Diabetic Macular Oedema

09:56 Mariacristina Parravano (Italy)

Prognostic imaging biomarkers in diabetic macular oedema treated with anti-VEGF: an AI perspective

10:05 David Wright (UK)

Selecting measures of visual function to classify diabetic retinopathy status

10:14 Ruth Hogg (UK)

The association between hypoglycaemia and visual function measured using a smartphone home-monitoring app in patients with diabetes

10:25 Session conclusions by the moderators

10:30 Break, exhibition, networking, refreshments

11:00 Session 2: Experimental and translational research

Chairs: Reinhold Medina Benavente; Eleni Beli

Oral presentations; 6 mins + 3 minutes questions

11:00 Moderator's introduction to session

11:02 Antonio Ambrosio (Portugal)

Texture-based OCT analysis reveals very early retinal alterations in type 2 diabetic animals: exploring a potential approach for early diagnosis of diabetic retinopathy

11:11 Hugo Ramos (Spain)

Sitagliptin prevents diabetes-induced hyperpermeability in human retinal endothelial cells and retinal pigment epithelium: the two major constituents of the blood retinal barrier

11:20 Pietro Maria Bertelli (UK)

Accelerated cellular senescence in retinal endothelial cells exposed to a diabetic microenvironment

11:29 Jose Hombrebueno (UK)

Targeting mitochondrial hyperfusion with human-compatible medications for neuroprotection in diabetic retinopathy

11:38 Francisco Martín-Loro (Spain)

MP-004, a small molecule developed to stabilize calcium channels (RyR), as a new therapy for diabetic retinopathy

11:47 Eleni Beli (UK)

The impact of misalignment with the external light cycle on the vasculature in diabetic retinopathy

11:56 Varun Pathak (UK)

Circadian rhythms of retinal microglia in early diabetes

12:05 Session conclusions by the moderators 2 minutes

12:10 Keynote lecture (20 mins + 10 discussion)

Professor David Preiss, University of Oxford (UK)

‘Fenofibrate, an efficacious and cost-effective treatment for diabetic retinopathy: results from the LENS trial’

12:45 Lunch, exhibition, networking

Poster presenters to take precedence

13:15 Session 3: Poster session

Poster presenters free to circulate after 45 mins

Poster Section 1 - Experimental research and translational

1. Jasenka Guduric-Fuchs (UK)

Senescence and circadian rhythms in endothelial colony forming cells

2. Judith Lechner (UK)

Investigating the role of the APC/EPCR pathway in endothelial progenitor cells in diabetic retinopathy

3. Tetiana Zhmud (Ukraine)

Low-dose Hydrocortisone and sodium hyaluronate improves conjunctival cytology among T2DM patients

4. Paola Serrano Martinez (Netherlands)

Use of stem cell-derived vascular organoids to study microvascular changes in diabetic retinopathy

5. Anna Deàs-Just (Spain)

Unravelling the common mediators of retinal and brain diabetes-induced neurodegeneration

Poster Section 2 - Diabetic retinopathy screening A

6. **Paul Coker (UK)**
The impact of cessation of screening for diabetic retinopathy during Covid-19 on people living with diabetes in Wales and England
7. **Rebecca Thomas (UK)**
The impact of cessation of screening for diabetic retinopathy during Covid-19 on ophthalmology services
8. **David Owens (UK)**
Impact of COVID-19 pandemic on the progress of diabetic retinopathy in Wales, UK
9. **Linda Ilavska (Slovakia)**
Artificial Intelligence-based screening for diabetic retinopathy in Type 2 Diabetes Mellitus using non-mydriatic fundus imaging
10. **Paula Summanen (Finland)**
Screening of diabetic retinopathy in Uusimaa, Finland: University Clinic service to communities in 2016-2019
11. **Karin Krogh (Norway)**
Diabetic Retinal Screening in Finnmark
12. **Roger Brint (UK)**
The Positive impact of the Hospital Eye Service (HES) recall initiative on patient care
13. **Jozef Lacka (Slovakia)**
Factors affecting diabetic retinopathy screening: reality and the influence of patient education

Poster Section 3. Diabetic retinopathy screening B

14. **Richard Hancock (UK)**
Usefulness of OCT in Diabetic Eye Screening
15. **Daniel Broderick (Ireland)**
Incidental ocular pathologies in the Irish Diabetic RetinaScreen Programme
16. **Lars Skollerud (Denmark)**
Training and validation of an automated algorithm to classify more than mild diabetic retinopathy in ultrawide-field images
17. **Lazaros Konstantinidis (Switzerland)**
Accuracy of autonomous artificial intelligence-based diabetic retinopathy screening of early stages of diabetic retinopathy
18. **Jelena Cuk (Serbia)**
First steps in diabetic retinopathy screening in Serbia
19. **Jelena Cuk (Serbia)**
Diabetic screening program in the North Backa District (Serbia): an observational study in cooperation with the Subotica Institute for Public Health
20. **Alberto Piatti (Italy)**
Diabetic retinopathy screening telemedicine-based compared to standard of care: an economic analysis in a pilot experience of Italian Healthcare
21. **Laura Cushley (UK)**

Evaluating progression and outcomes following the integration of Diabetic Eye Screening Programme into Haemodialysis Units in Northern Ireland

22. Shweta Pandey (UK)

A new service initiative of opportunistic retinal screening of inpatients with diabetes in Gloucestershire Hospitals NHS Foundation Trust

Poster Section 4. Systemic and epidemiology

23. Bénédicte Dupas (France)

Florid diabetic retinopathy in young patients with uncontrolled diabetes: a long-term follow-up

24. Olga Simó-Servat (Spain)

Diabetic retinopathy is a major and independent predictor of cardiovascular disease in subjects with type 2 diabetes

25. Lika Tsutskiridze (Georgia)

Promotion of rights of Children with Diabetes - Our first summer camp for children and adolescents with Type 1 Diabetes

26. Ayesha Malik (UK)

Corneal confocal microscopy: A marker of neurodegeneration in Parkinson's Disease

27. Sarah Meredith (UK)

Prevalence of people eligible for diabetic eye screening and the rate of detection of R3 proliferative features in a large English population 2018 – 2024

Poster Section 5: Clinical studies

28. Katie Curran (UK)

Outcomes after Pan-retinal photocoagulation Laser treatment in people with Proliferative Diabetic Retinopathy

29. Rosalind Creer (UK)

The evolution of the enhanced Diabetes Assessment Clinic

30. Maria Grazia Pignataro (Italy)

Long-term impact of diabetic Retinopathy on response to anti-VEGF treatment in Neovascular AMD

31. Charles O'Donovan (UK)

Transforming FFA consent: The impact of Concentric at Moorfields Croydon

32. George Zelhof (UK)

Real-world outcomes of intravitreal Faricimab in Diabetic Macular Oedema: Adherence to a personalised treatment regime protocol is challenging

33. Blazej Staniszewski (UK)

Biosimilar Ranibizumab for Diabetic Macular Oedema: A retrospective study of visual and anatomical outcomes in treatment-naive patients

Poster Section 6: Imaging

- 34. Ana Catarina Almeida (Portugal)**
Retinal neurodegeneration in eyes with mild to severe non-proliferative diabetic retinopathy: One year analysis of CHART study
- 35. Kim Lien Huber (Austria)**
Reduced ellipsoid zone reflectivity in advanced diabetic retinopathy as assessed by high-resolution optical coherence tomography
- 36. Nina Hautala (Finland)**
Efficacy of diabetic macular oedema detection in fundus images using iCare DRSplus and Zeiss Visucam
- 37. Sema Tamer Kaderli (Turkey)**
Analysis of the Henle fibre layer thickness and area in patients with non-proliferative diabetic retinopathy
- 38. Paul Widmann-Sedlnitzky (Austria)**
Volumetric changes in hyperreflective foci and hard exudates in diabetic macula oedema managed with faricimab
- 39. Fu Wang (UK)**
AI-Driven segmentation of Langerhans-cells in corneal confocal microscopy images
- 40. Ayça Küpeli Çınar (Turkey)**
Demographic data and fundus fluorescein angiography findings of treatment-naïve patients with diabetic maculopathy: 1-year single-centre real-life data
- 41. Kim Gooding (UK)**
Preliminary study exploring whether retinal and sublingual microvascular densities are associated in individuals with type 2 diabetes

14:30 Tea/coffee served at exhibition and poster sessions

14:50 Session 4: Systemic management and eye complications

Chairs: Uazman Alam;

Oral presentations of 5 minutes (discussion and questions at the end of the session)

14:50 Moderator's introduction to session

14:52 The winner of the Anne Katrin Sjolie best student abstract prize: Matthew Anson (UK)

The rapidly increasing incidence of diabetic retinopathy disproportionately affects younger age groups: a decade of evidence from an international federated database

14:57 Jakob Grauslund (Denmark)

Once-weekly semaglutide doubles the five-year risk of non-arteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.

15:02 Philip Burgess (UK)

Incidence and determinants of early worsening of diabetic retinopathy in the Individualised Screening for Diabetic Retinopathy Cohort Study

15:07 Ali Erginay

Effect of new non-insulin antidiabetic drugs on retinal capillary perfusion assessed in OCT-A

15:12 David Riley (UK)

Is liver fibrosis associated with retinal health in prediabetes and Type 2 diabetes? Findings from IDENTIFY Complications T2D

15:17 Stela Vujosevic (Italy)
Diabetic retinopathy and macular microvascular differences between eyes: the impact of cerebrovascular comorbidities

Mini-lecture 10 minutes

15:22 Tom Gardner (USA)
It is time to restore vision in persons with diabetic retinal disease

15:32 Session discussion 10 minutes

15:45 Keynote lecture (20 mins; 10 minutes discussion)

Introduction: Uazman Alam

Speaker: Rayaz Malik

'The eye: the window to the soul and beyond'

16:15 Eva Kohner Lecture (35 mins)

Chair: Reinier Schlingemann

Awardee: Professor Jennifer Sun, Boston, USA

Title to be confirmed

17:00 Annual General Meeting

17:30 End of day

19:00 Conference dinner at Liverpool World Museum

SATURDAY, 7th JUNE 2025

08:30 Registration

09:00 Session 5: Screening

Chairs: Tunde Peto;

09:00 Moderator's introduction to session

09:02 Caroline Styles (UK) (10 minutes)

Diabetic Retinopathy Screening in Europe – Building on 20 years of Progress. Summary of meeting, 5th June 2025.

Rapid fire oral presentations (4 minutes; title slide + 2 slides)

09:12 Andreas Pollreis (Austria)

Multiethnic diabetic retinopathy prediction model using AI-based risk-scoring in Singapore

09:16 Maria Sole Polito (Italy)

Performance of DRSplus ophthalmic camera in patients with diabetes mellitus: a comparison study of human consensus grading, Reading Centre and Artificial Intelligence grading results

- 09:20 Sebastian Dinesen (Denmark)**
Automatic segmentation-assisted classification of active proliferative diabetic retinopathy using deep learning
- 09:24 Toke Bek (Denmark)**
Individualised screening for diabetic retinopathy with proliferative diabetic retinopathy and diabetic macular oedema as separate end points
- 09:28** Discussion 5 minutes
- 09:33 Philip Burgess (UK)**
Five-year treatment rates following referral for sight threatening diabetic retinopathy from a systematic screening programme
- 09:37 Bridget Moran (Ireland)**
Evaluation of biennial screening outcomes in RetinaScreen, Ireland's National Diabetic Retinopathy Programme
- 09:41 Rebecca Thomas (UK)**
The recovery of diabetic eye screening in Wales following the Covid-19 pandemic
- 09:45 Catherine Jamison (UK)**
Combined diabetic eye and foot screening in a remote region of Tanzania
- 09:50** Discussion 8 minutes
Session conclusions by the moderators 2 minutes
- 10:00 Keynote lecture (20 mins; 10 minutes questions)**
Speaker Alexander Doney, Dundee
Chair Reinhold Medina
'AI-based precision prediction of future cardiometabolic complications beyond diabetic retinopathy using Scottish diabetes retinal screening photographs and clinical data'
- 10:30 Break, exhibition, networking, refreshments**
Posters available for discussion
- 11:00 Session 6: Translational session**
Chairs: Ingeborg Klaassen, Tom Gardner
Oral presentations; 5 minutes + 2 minutes questions
- 11:00** Moderator's introduction to session
- 11:00 Tunde Peto (UK)**
Descriptive analysis of anatomic outcomes after anti-VEGF treatment in a UK Diabetic Macula Oedema cohort using automated OCT segmentation
- 11:07 Lasse Jørgensen Cehofski (Denmark)**
Protein changes associated with incomplete response to anti-VEGF therapy in Diabetic Macular Oedema: Integration of proteomics and Artificial Intelligence
- 11:14 Ingeborg Klaassen (Netherlands)**
Exploring the use of aqueous taps to monitor vitreous protein levels in proliferative diabetic retinopathy and their associations with clinical parameters
- 11:21 Patrice Fort (USA)**

11:28 Session conclusions by the moderators 2 mins

11:30 Session 7: Novel Imaging & Pathophysiology

Chairs: Savita Madhusudhan; Ines Pereira Marques

Oral presentations; 5 minutes + 2 minutes questions

11:30 Moderator's introduction to session

11:32 Ines Pereira Marques (Portugal)

Progression of capillary perfusion in advanced stages of NPDR: 1-year analysis of the RICHARD study

11:39 Laura Kunze (Austria)

Adaptive optics OCT reveals distinct changes of microstructures relevant for diabetic retinopathy in humans

11:46 Caterina Toma (Italy)

OCT-angiography and colour fundus autofluorescence in type 1 diabetes mellitus and pre-clinical diabetic retinopathy

11:53 Line Peterson (Denmark)

Increased amplitude of ultra-high frequency (UHF) vasomotion in retinal arterioles from patients with vision threatening diabetic retinopathy

12:00 Flavia Chiosi (Italy)

The impact of Hypertension on choroidal vascular parameters in Type 2 Diabetes: a correlative study of retrobulbar haemodynamics and OCT Angiography

12:07 Session conclusions by the moderators 2 minutes

12:10 Debate

Motion: 'Adjuvant macular laser is indicated when response to anti-VEGF treatment for DMO is suboptimal'

For: Reinier Schlingemann, Amsterdam

Against Richard Gale, York, UK

12:45 Best poster prize ceremony and closing remarks

President of EAsDEC Reinier Schlingemann

13:00 Conference close
